{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:53:06Z","timestamp":1777657986952,"version":"3.51.4"},"reference-count":28,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s434556","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T08:00:19Z","timestamp":1707379219000},"page":"59-73","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study"],"prefix":"10.2147","volume":"Volume 20","author":[{"given":"Li-Jen","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-7291","authenticated-orcid":true,"given":"Benfa","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhuram","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1756-8722-3-21","volume":"3","author":"Chen","year":"2010","journal-title":"J Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","volume":"9","author":"Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"ref6","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of relapsed\/refractory acute myelogenous leukemia (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):624\u2013627. doi:10.3760\/cma.j.issn.0253-2727.2021.08.002"},{"key":"ref7","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):617\u2013623. doi:10.3760\/cma.j.issn.0253-2727.2021.08.001"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","volume":"5","author":"Thol","year":"2021","journal-title":"HemaSphere"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cancers14051164","volume":"14","author":"Nitika","year":"2022","journal-title":"Cancers"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1002\/cam4.3467","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"ref18","unstructured":"Astellas Pharma Inc. Astellas\u2019 XOSPATA\u00ae (gilteritinib) receives conditional approval by china\u2019s national medical products administration for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Available from: https:\/\/newsroom.astellas.us\/2021-02-03-Astellas-XOSPATA-R-gilteritinib-Receives-Conditional-Approval-by-Chinas-National-Medical-Products-Administration-for-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-with-A-FLT3-Mutation. Accessed September 22, 2022."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/ejh.13205","volume":"102","author":"Griffin","year":"2019","journal-title":"Eur J Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/MOH.0000000000000561","volume":"27","author":"Koenig","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e12102","DOI":"10.1097\/MD.0000000000012102","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine"},{"key":"ref26","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017). Zhonghua Xue Ye Xue Za Zhi. 2017;38(3):177\u2013182. doi:10.3760\/cma.j.issn.0253-2727.2017.03.001"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref28","unstructured":"Acute myeloid leukemia \u2014 cancer stat facts. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed June 29, 2023."}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96633","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T08:00:23Z","timestamp":1707379223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/treatment-patterns-and-flt3-mutation-testing-among-patients-with-acute-peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s434556","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}